Rapid response to high-dose Anakinra in refractory SLE-associated Haemophagocytic Lymphohistiocytosis: a case report
S Jain, N Soe, K Sandhu, J McNally · 2026
Read Rapid response to high-dose Anakinra in refractory SLE-associated Haemophagocytic Lymphohistiocytosis: a case report by S Jain, N Soe, K Sandhu, J McNally (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13612240.txt.
Description
Four doctors report a case where a higher dose of a drug rescued a woman from a life-threatening immune storm, in this 2026 case report. The condition, HLH, makes the immune system attack the body itself. Their patient, aged forty-seven, developed it on top of lupus and a COVID infection. Standard treatment with steroids and immune-suppressing drugs worked at first, then the disease flared again.
The team raised the dose of anakinra, a drug that blocks a key inflammation signal. On the higher dose, she recovered and stayed in remission. Similar rescues have been reported with other triggers of the same storm. The authors argue high-dose anakinra should move to first-line use when standard doses fail, since untreated disease is often fatal. They add a caution: blocking that signal can invite infection, so close watching is part of the bargain.
Catalog record
| CREATOR | S Jain, N Soe, K Sandhu, J McNally |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |